



**HotSHOT - Reporting Octaplas SAR and SAE**

Octaplas is a sterile, frozen solution of pooled human plasma from several donors that has been treated with a solvent detergent process. Octaplas is a manufactured blood product, as such all SAR should be reported to the MHRA via the [yellow card scheme](#), as with other blood products. In addition to this [SHOT](#) accept SAR and SAE relating to Octaplas.



**Symposium/Events**

The [2021 BBTS Conference](#) takes place 13-15 September 2021.

The SHOT team will be at BBTS, we are hosting a session with Quality Improvement on Tuesday 14 September 9-10am.

We will also be presenting on 'Learning from Excellence' at the plenary 4 session on Wednesday 15 September 11-12:30.

Please do also visit us on our stand—we look forward to seeing you there.

**Upcoming Events**



[IHN virtual mini-seminar](#)  
28 September 2021:



**Resources update**

The [2020 Annual SHOT Report](#) foldable summaries are now available to order at <https://hospital.nhsbtleaflets.co.uk/> under stock code blc789-1.


Also now available:

The SHOT Team published Safe transfusions in haemopoietic stem cell transplant recipients guidance document in July 2021. The document has now been updated to include instructions for CMV matching for granulocytes. [See News item](#).



This year, to complement the Annual SHOT Report the working expert group have been providing short audio summaries for their chapters.

You can access these on the [SHOT website](#) along with the relevant individual chapter. More will be added as they become available.



**Spotlight - SHOT Laboratory Incident specialist**

SHOT Laboratory Incident Specialist, Vicky Tuckley, will shortly be going on maternity leave—we wish her all the best for a happy and restful maternity leave!

Whilst Vicky is away we are fortunate to have Nikki Swarbrick joining the team as the laboratory incident specialist. Nikki has huge experience in laboratory transfusion practice and will be a great asset.

Nikki will be starting on 13 September 2021 and can be contacted at [nicola.swarbrick@nhsbt.nhs.uk](mailto:nicola.swarbrick@nhsbt.nhs.uk)

**Opportunities at SHOT**

We are looking for expressions of interest to **join our Working Expert Group** in the following areas:


- [Avoidable, Delayed or Under/Overtransfusion \(ADU\) and Incidents Related to Prothrombin Complex Concentrate \(PCC\)](#)
- [Adverse Events Related to Anti-D Immunoglobulin \(Ig\)](#)
- [Near Miss \(NM\) Reporting](#)

Applicants should state how they have expertise in this area, provide a CV to demonstrate that, and details of two referees. Please contact the SHOT office for further information at [shot@nhsbt.nhs.uk](mailto:shot@nhsbt.nhs.uk) or call 0161 423 4208.

**Applications should be sent to Jeni Davies**, SHOT Operations Manager at [jeni.davies@nhsbt.nhs.uk](mailto:jeni.davies@nhsbt.nhs.uk) by **3 September 2021**. An informal interview will be held towards the end of September 2021.

The SHOT Team

SHOT Office, NHS Blood & Transplant, Manchester Blood Centre, Plymouth Grove, M13 9LL  
Tel: 0161 423 4208  
[shot@nhsbt.nhs.uk](mailto:shot@nhsbt.nhs.uk) | [www.shotuk.org](http://www.shotuk.org) | [twitter.com/shothv1](https://twitter.com/shothv1)



If you would prefer not to receive haemovigilance communications from SHOT, then please email [SHOT.unsubscribe@nhsbt.nhs.uk](mailto:SHOT.unsubscribe@nhsbt.nhs.uk) and you will be removed from the distribution list.